5paisa Q1: revenue +14% YoY, consolidated PAT flat at ₹11.6 Cr as margins compress
PAT +0.18% YoY · revenue +13.7% · margins compressing
₹88.33 Cr
+13.7% YoY
₹11.57 Cr
+0.18% YoY
13.09%
-1.8pp YoY
₹2.6
5paisa Capital's consolidated Q1 FY27 (quarter ended June 30, 2026) print was a growth-without-operating-leverage quarter: revenue from operations rose 13.7% YoY to ₹88.33 Cr, but net profit was essentially flat at ₹11.57 Cr versus ₹11.55 Cr a year ago (+0.2%). The topline was carried by interest income, up 26.5% YoY to ₹42.17 Cr as the company began deploying rights-issue capital into its MTF/funding book; fees and commission income grew a softer 4.1% to ₹46.16 Cr, pointing to muted brokerage momentum. The disconnect between double-digit revenue growth and flat profit sits in costs — other expenses jumped ~25% YoY to ₹40.17 Cr — dragging net margin down to 13.1% from 14.85% a year earlier (though up sequentially from 12.7% in Q4). Management's own annexure pegs operating margin at 17% and NPM at 13%.
Q1 FY-2027 vs prior quarters
The standout for shareholders is EPS: basic EPS fell to ₹2.60 from ₹3.70 YoY despite flat PAT, purely a dilution effect from the ₹468.82 Cr rights issue that lifted the share count ~50% (paid-up capital ₹31.25 Cr → ₹46.88 Cr). This is the first full quarter reflecting that expanded base. On QoQ terms revenue rose 3.4% and PAT 6.6% off the March quarter, but the year-on-year comparison — flat profit on 14% higher revenue — is the honest read.
The stock went into the print at ₹384, up 17.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Standalone near-identical — PAT ₹11.50 Cr on revenue ₹88.33 Cr, EPS ₹2.58 — subsidiaries immaterial
Management provided strategic guidance centered on deploying the recently raised INR 468 crores from its successful rights issue to fuel long-term growth. Capital is earmarked for supporting higher trading volumes, significantly expanding the MTF funding book, and funding core business expansion through investments in
Against prior guidance, management gave no quantitative targets on the Q4 concall, only a qualitative plan to deploy the ₹468 Cr raise into higher trading volumes, a larger MTF book, and tech/AI investment; this quarter's 26.5% jump in interest income is directionally consistent with that, but the promised growth has not yet reached the bottom line. No street consensus is available for this small-cap. Two regulatory overhangs bracket the print: the ₹33.02 Cr income-tax demand (under CIT(A) appeal, not provisioned) and a June-2026 SEBI show-cause notice on Investment Adviser registration. There is no management press release on record for this result.
What to watch
W1
MTF/funding book scale-up: interest income at ₹42.17 Cr (+26.5% YoY) is the growth driver post rights issue — watch if it sustains and starts converting to profit
W2
Margin trajectory: NPM 13.1% vs 14.85% YoY, with other expenses +25% YoY — verify whether cost growth continues to erode margins next quarter
W3
₹33.02 Cr income-tax demand — outcome of the CIT(A) appeal and any provisioning; plus the June-2026 SEBI show-cause notice on Investment Adviser registration
Clean digital PDF, ₹ in lacs. No exceptional items in either period. ₹33.02 Cr income-tax demand (Jan-2025 search, block period FY19-FY25) flagged as Emphasis of Matter — under CIT(A) appeal, NOT booked in P&L. EPS fell YoY due to ~50% share-count rise from the ₹468.82 Cr rights issue (capital ₹31.25→₹46.88 Cr). Consolidated and standalone virtually identical (subsidiaries negligible).
Revenue +14%, PAT Flat: The Execution Gap Widens
5paisa reported ₹88.3 Cr revenue (up 13.7% YoY) and ₹11.6 Cr net profit (up just 0.2% YoY). The gap between these two numbers — and the market's 5% sell-off post-result — reveals the quarter's real story: a company mid-bet on product ramps, with profit growth already stalled despite a fresh ₹468 Cr capital raise.
₹88.3 Cr
+13.7% YoY | +3.4% QoQ
₹11.6 Cr
+0.2% YoY | +6.6% QoQ
29.5%
stable YoY
13.1%
steady but limited leverage
The disconnect: where did revenue growth go?
Revenue grew 13.7% year-over-year — a respectable performance in a choppy market. But net profit grew only 0.2%, up just ₹23 lakh in absolute terms. Operating profit margin held steady at 29.5%, which at first glance looks disciplined. The catch: stable margin × higher revenue should compound to faster profit growth. It didn't. That means operating expenses rose faster than revenue, absorbing the top-line gains and negating the leverage investors expected from the ₹468 Cr capital raise in April.
Management's claims graded
Revenue grew 14% YoY to ₹88.4 Cr
₹88.3 Cr, +13.7% YoY
Supported (rounding up)
PAT of ₹11.6 Cr
₹11.6 Cr exactly
Supported
Q1 slowness is 'slightly one-off'; growth will accelerate from these quarters on
QoQ revenue +3.4%, PAT +6.6%; no recovery timeline specified
Overstated (vague timeline)
MTF has doubled over 15 months, showing encouraging growth
₹422 Cr MTF book, +3% QoQ; MF AUM ₹2,073 Cr, +18% QoQ
Unverified (absolute MTF doubling not in result)
Platform revamp beta results are 'very, very encouraging'
No user adoption metrics, revenue impact, or timeline disclosed
Unverified (no specifics)
What changed on this call
Capital deployment clarity. Prior guidance was strategic intent; this call confirmed specifics: ₹227 Cr for exchange margin (RBI mandate), ₹150 Cr for debt repayment, ₹88 Cr for product/tech/marketing. Deployment is on track—a plus. But translating spend into revenue remains unproven.
Platform revamp elevated. Not mentioned in prior calls; now positioned as the core growth driver for Q2 onwards. AlgoSpace algo trading launch, AI-powered portfolio insights, and T+5 leverage (2,500 eligible scrips) are being rolled out. Beta feedback is positive, but unspecified. Market will need concrete adoption numbers to reward this bet.
PAT growth trajectory stalled. The most concerning shift: despite ₹468 Cr in fresh capital and a renewed product roadmap, PAT grew 0.2% YoY. This suggests either (a) reinvestment spending is higher than expected, or (b) the ADTO slowdown (F&O volumes down QoQ; management acknowledged a dip on F&O post-October 2024 regulatory changes) is heavier than embedded in prior models. Either way, management's confidence in near-term profit recovery is unsubstantiated by Q1 delivery.
Bull-bear ledger
Fresh capital (₹468 Cr) deployed for scale and product ramps
MTF and MF AUM growing; portfolio diversification and customer wallet-deepening progressing
Retail financialization and trading volume tailwind remain structural
PAT growth at 0.2% YoY; flat despite revenue +13.7% signals execution gaps
QoQ revenue +3.4% weak; momentum stalling post-capital raise
F&O regulation (October 2024 RBI intraday ban) suppressing volumes; recovery timeline vague
Product ramps (platform, AlgoSpace, AI insights) unproven; 'very encouraging' beta results unspecified
Customer acquisition slowdown acknowledged; pivoted to 'quality over quantity' (potentially defensive)
Risks ranked by severity
PAT growth stalled (0.2% YoY) despite revenue +13.7%
HighSignals either reinvestment overruns or volume headwinds not fully disclosed. If this becomes the norm, shareholder payback will disappoint. Operating leverage—a core bull argument—is not materializing.
Product ramps unproven; platform revamp adoption unspecified
HighEntire growth narrative now rests on platform adoption (revamp, AlgoSpace, AI). Management claims 'very encouraging' beta but has not disclosed user adoption %, conversion %, or revenue impact. If adoption is slow or features undermonetize, growth remains muted.
Customer acquisition slowness; pivoted to 'quality over quantity'
MediumIf 'quality' is code for accepting slower headline growth to improve unit economics, 5paisa becomes a low-growth story. Analyst Jatin Sahani pressed on this; management deflected. Follow-up needed.
F&O regulation headwinds persist; no recovery timeline
MediumOctober 2024 RBI intraday ban suppressed F&O ADTO. Management acknowledged 'moderation' and 'choppy' past year but offered no timeline for recovery. If large-cap brokers diversify faster, 5paisa loses incremental volumes.
Market share dynamics unclear; competitive intensity rising
MediumManagement acknowledged post-regulation 'some gained, some lost' but would not quantify 5paisa's position. Large brokers (Zerodha, others) have scale and capital; if they move upmarket into MTF or fintech, 5paisa's mid-tier positioning erodes.
How the street is positioned
Price action says the market wasn't impressed. The result was announced at ₹384 (the pre-close price). On day 1, the stock fell 5.34% (delivery 49.2%, a heavy sell-off), and the decline held: day 3 saw a further 2.08% drop, and by day 5 it was down 4.44%. As of 2026-07-31, the stock trades at ₹348.15, now 13.38% below its all-time high but still up 42.1% off its 52-week low. The drawdown is material but not catastrophic, and the stock remains above its 200-day average (₹327.97).
The sell-off is the market's own verdict: a company with solid reported numbers and a credible growth roadmap, but with profit growth that has already stalled despite fresh capital. The market is asking, not unreasonably, whether management can deliver on the platform ramps before investor patience—and execution risk—wear thin.
Foreign institutions are buying; domestic are absent. FII ownership rose sharply from 12.41% in Q4 FY26 to 15.07% in Q1 FY27, a gain of 2.66 percentage points. Promoters also increased their stake from 32.77% to 36.50% (+3.73pp), suggesting conviction. But domestic institutions remain absent (DII flat at 0.01%). The foreign buying may reflect a long-term bet on India fintech, or a rebalancing into mid-cap brokers post-sell-off; the domestic silence is notable and hints at local hesitation on valuation or execution.
The debate
What to watch next
1 · Q2 revenue momentum and QoQ guidance
Q1 QoQ revenue was +3.4%—weak. If Q2 shows acceleration (low-to-mid teens QoQ), platform ramps are gaining traction. If Q2 is another low-single-digit quarter, the momentum is broken and the thesis weakens materially.
2 · Platform revamp adoption metrics
Management must disclose: new-user adoption rates on revamped platform, % of active users on new platform, early monetization per user. 'Very encouraging beta results' is not a number. Concrete adoption data will separate execution from hype.
3 · PAT growth recovery
If Q2 PAT grows double-digit YoY (or better, if OpEx as a % of revenue declines), the 0.2% YoY number becomes a true one-off and the capital deployment is bearing fruit. If Q2 PAT growth remains low-single-digit or flat, the reinvestment cycle is not paying off and profit multiples will compress.
The single number to track
Net Profit YoY growth. Q1 managed 0.2% — a red flag in a ₹88+ Cr revenue base. For a company that just raised ₹468 Cr and is mid-bet on product ramps, PAT growth is the scorecard for execution. If Q2 shows low-single-digit PAT growth, or if margins begin to compress, the bull thesis is in trouble. A return to 15%+ PAT growth (which was the baseline before the capital raise) would confirm management's roadmap is working. Anything in between is a muddy signal that keeps the stock range-bound.
5paisa is not a broken story—it's a company mid-transition. The capital raise was real, the product roadmap is credible, and the fintech tailwind is structural. But the Q1 quarter revealed a hard truth: revenue growth is healthy, but profit growth has stalled. That gap is either temporary (a necessary reinvestment cycle that pays off in Q2–Q3) or a signal that execution will be harder than management's confidence suggests. The stock's 5% day-1 sell-off and 13% drawdown from the all-time high reflect this honest uncertainty. The debate will not settle until the next two quarters prove whether the platform ramps and capital deployment can re-accelerate PAT growth. Until then, 5paisa remains a hold for long-term believers in India fintech, but a pass for investors seeking near-term profit acceleration.
Platform revamp bet: growth stalls, capital deployed, execution unproven
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Q1 missed implied PAT growth expectations (0.2% YoY vs implied higher run-rate post-capital raise). Prior guidance centered on deployment, which is on track.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
5paisa is executing on a strategic capital deployment (₹468 Cr) and platform modernization, but Q1 revealed execution risk: PAT grew only 0.2% while revenue grew 13.7%, and QoQ momentum is weak (+3.4% rev). Management's confidence in product ramps is unsubstantiated by delivery. Key risk: execution on promised platform revamp and return on marketing spend.
₹88.3 Cr
Revenue · +13.7% YoY₹11.6 Cr
Reported PAT · +0.2% YoYFlat
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 14% YoY to 88.4 crores
METDelivered ₹88.3 Cr, YoY +13.7% (not 14%)
PAT of 11.6 crores
METDelivered ₹11.6 Cr PAT, exact match
Q1 moderation was slightly one-off, growth to accelerate
OVERSTATEDQoQ revenue only +3.4%, PAT +6.6%; no specific recovery timeline given
MTF has doubled from 15 months, shown encouraging growth
UnverifiedMF AUM at ₹2,073 Cr (+18% QoQ); specific MTF book not in delivered result
Better RPC and LTV observed in metrics
UnverifiedNo RPC/LTV metrics in delivered result; claimed in Q&A but unverified
Earnings quality
What changed since the last call
Capital deployment specifics disclosed
UpgradePrior guidance was strategic intent; this call confirmed ₹227 Cr to exchange margin (RBI mandate), ₹150 Cr debt, ₹88 Cr corporate—providing transparency on allocation.
PAT growth trajectory stalled
DowngradeQ1 PAT grew only 0.2% YoY vs prior expectations of benefit from capital raise and product initiatives; OPM flat at 29.5% suggests expense discipline losing.
Platform revamp elevated as near-term driver
NewNot mentioned in prior calls; now central to growth narrative. Beta results cited as 'very encouraging' but unspecified; execution risk high.
The Q&A
Analyst Jatin Sahani directly challenged slowness: Q3/Q4 were good, Q1 slow—is this one-off? Management acknowledged 'moderation' but vague on recovery. Follow-ups on ADTO and customer acquisition were partially dodged; management pivoted to quality strategy rather than addressing volume decline.
Q1 growth moderation — Jatin Sahani, Individual Investor
PartialSlightly one-off due to market volatility; we expect growth to accelerate given product improvements and growth marketing efforts.
ADTO and customer acquisition slowdown — Jatin Sahani, Individual Investor
DodgedFocus on quality over quantity; seeing improvement in RPC and LTV; long-term customers drive high ADTO; will continue this approach.
Market share dynamics — Jatin Sahani, Individual Investor
DodgedHard to say precisely; after F&O regulation changes in Oct '24, moderation across board; our strategy is quality retention and MTF; long-term market will grow.
Capital deployment (₹468 Cr) — Amit Mehendale, Robo Capital
Answered₹227 Cr for exchange margin (RBI mandate), ₹150 Cr debt repayment, ₹88 Cr corporate purpose (product, tech, marketing). Already deployed.
Revenue growth acceleration — Amit Mehendale, Robo Capital
PartialPlatform revamp (happening, beta results very encouraging), growth marketing spend (now well-positioned post-capital raise), couple of pipeline products coming; MTF already showing traction.
Customer acquisition channels — Amit Mehendale, Robo Capital
PartialFocus on quality organic and paid channels; refining channel mix quarterly based on CAC/RPC metrics; organic works best but takes time.
Third-party distribution (TPD) — Amit Mehendale, Robo Capital
DodgedNot in near future; hands full with core platform. Mid-term, might explore if synergies exist. Focus on products adjacent to core (MTF, LAS) first.
Guidance
No specific FY27 revenue target; expect acceleration from Q2 onwards
LowVague timeline ('from these quarters on'); tied to unproven product ramps (platform revamp, AlgoSpace, pipeline products).
No margin target; focused on unit economics and operating leverage at scale
LowManagement says pursuing 'meaningful improvements in unit economics' but no numbers or timeline; Q1 PAT flat suggests execution challenge.
₹88 Cr from capital raise allocated to product, tech, marketing; no additional capex guidance
MediumCapital deployment plan clear; execution against it (ROI on marketing, product adoption) is the variable.
Risks the call surfaced
Product execution risk
HighPlatform revamp positioned as key growth driver; beta results 'very encouraging' but unspecified. AlgoSpace targeting retail algo adoption (first-time builders); unknown market size. If adoption falls short, growth target missed.
Market volatility & macro headwinds
MediumF&O regulatory change (Oct '24, RBI intraday ban) caused ADTO dip on F&O; past year 'choppy'. Q1 showed market moderation effect; future quarters subject to equity bull/bear cycles.
PAT growth stalling
MediumPAT grew only 0.2% YoY despite 13.7% revenue growth; suggests operating expense rise (likely product/tech/marketing investment). If ROI on this spend is low, PAT leverage will not materialize.
Customer acquisition & retention
MediumManagement acknowledged 'slowness' in customer acquisition and ADTO growth; pivoted to quality over quantity strategy. If quality strategy is defensive (not growth-oriented), headline growth will remain muted.
Competitive pressure
MediumManagement acknowledged 'some people have gained market share, some people have lost' post-F&O regulation. Large brokers have scale and capital; 5paisa's quality positioning may not be sufficient if price competition intensifies.
Management
Score 6/10. Mixed transparency. Specific on capital deployment (₹227 Cr exchange margin, ₹150 Cr debt, ₹88 Cr corporate purpose) but vague on product ramps ('very encouraging' beta results unspecified). Withheld pipeline product details. Capital raise deployed on schedule (April). Product roadmap underway (15-18 months work on platform). But PAT growth flat (0.2% YoY) despite revenue +13.7%, indicating execution gaps or expense overruns vs expectations.
1 · Q2 FY27
Platform revamp and AlgoSpace algo trading launch; retail adoption unknown
2 · H2 FY27
Product pipeline 'couple of things' for revenue generation; details withheld
3 · Next 12mo
Expansion into adjacent areas (organic/inorganic); no specific timelines or targets
Key risk: execution on promised platform revamp and return on marketing spend.